Global supply-chain fragility and orphan‑drug policies drive Sanofi's Pompe disease drug shortage
Original framing: “STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patients” — STAT News
Drug shortages are not new; the 2008 insulin shortage and earlier orphan‑drug crises reveal a pattern where market concentration and regulatory inertia repeatedly jeopardize patient access. Historical analysis underscores the need for policy reforms that institutionalise redundancy and contingency planning.
The Sanofi Pompe drug shortage is a symptom of a broader systemic fragility rooted in orphan‑drug market concentration, insufficient manufacturing redundancy, and opaque pricing regimes.
Historical precedents of insulin and other rare‑disease shortages demonstrate that without deliberate policy interventions, supply shocks recur, disproportionately harming marginalised patients across cultural contexts. By integrating scientific advances in bioprocessing, cross‑cultural lessons on shared responsibility, and the creative resilience of patient communities, a multi‑layered response—spanning regional production, pricing reform, global early‑warning mechanisms, and patient cooperatives—can transform scarcity into a catalyst for equitable, resilient health infrastructure.